Avalo Therapeutics Reports Widened 2025 Net Loss, Increased Cash Burn, and Significant Dilution Potential Amidst Insider Selling Plans
AVTX has more than doubled off its 52-week low of $3.39.
Summary
Avalo Therapeutics' 2025 annual report shows a widened net loss and increased cash burn, with significant potential dilution from its capital programs and notable insider selling plans, despite an extended cash runway into 2028.
Key Events · Earnings and Guidance · AVTX
-
Widened Net Loss and Increased Cash Burn
The company reported a net loss of $78.3 million for 2025, a significant increase from $35.1 million in 2024. Net cash used in operating activities also increased to $51.5 million in 2025 from $49.0 million in 2024.
-
Extended Cash Runway into 2028
Despite increased losses, Avalo Therapeutics projects its existing cash, cash equivalents, and short-term investments of $98.3 million (as of Dec 31, 2025) are sufficient to fund operations into 2028.
-
Significant Potential Dilution from Convertible Securities and ATM Program
As of December 31, 2025, 18,792 shares of Series C Preferred Stock were outstanding, convertible into approximately 18.8 million common shares. Additionally, the company sold 1.7 million common shares for $14.8 million under its $75.0 million At-The-Market (ATM) program in 2025, with approximately $60.2 million remaining available for future sales. If all convertible preferred stock and remaining ATM shares were issued, it would represent over 100% dilution to current outstanding common shares.
-
Multiple Insiders Adopt 10b5-1 Selling Plans
Five executive officers and directors adopted Rule 10b5-1 trading plans in November 2025 to sell an aggregate of 472,718 shares of common stock, valued at approximately $6.33 million based on the current stock price. This follows a Form 144 filing on March 16, 2026, for an officer to sell shares worth approximately $466,558.
Analysis · AVTX · Life Sciences
Avalo Therapeutics' 2025 annual report reveals a substantial deterioration in financial performance, marked by a significantly increased net loss and higher cash burn. While the company projects a cash runway into 2028, this is set against a backdrop of considerable dilution from its ATM program and convertible preferred stock. The adoption of 10b5-1 selling plans by multiple executives and directors signals a lack of insider conviction, further compounded by the recent expiration of the composition-of-matter patent for its lead candidate, AVTX-009. Investors should closely monitor the upcoming Phase 2 LOTUS trial data in Q2 2026, as it is a critical catalyst for the company's future, but remain cautious given the current financial strain and potential for further dilution.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1183 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVTX was trading at $13.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $248.4M. The 52-week trading range was $3.39 to $20.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.